High-grade sarcomas with myogenic differentiation harboring hotspot PDGFRB mutations Journal Article
| Authors: | Dermawan, J. K.; Chiang, S.; Hensley, M. L.; Tap, W. D.; Antonescu, C. R. |
| Article Title: | High-grade sarcomas with myogenic differentiation harboring hotspot PDGFRB mutations |
| Abstract: | PDGFRB-activating mutations have been reported in pediatric myofibroma and myofibromatosis. However, recurrent gain-of-function PDGFRB mutations have not been documented in sarcomas with myogenic differentiation. Driven by occasional sarcomas harboring PDGFRB mutations, we investigated their prevalence and clinicopathologic and genomic features in a large cohort of sarcomas. An institutional targeted DNA next-generation sequencing database was searched for sarcomas with myogenic differentiation harboring hotspot PDGFRB gene alterations. Among 3300 patients with sarcomas, 21 (0.6%) patients were identified (17 women, 4 men) with an age range of 35 to 88 years. The site distribution included 13 gynecologic tract (12 uteri, 1 vagina), 4 bone and soft tissue, and 4 viscera. All except 1 were high grade. Most patients were diagnosed as sarcomas with myogenic differentiation based on partial staining for 1 or more muscle markers, whereas 6 were labeled as leiomyosarcoma (LMS). Most tumors showed monomorphic spindle morphology, with either heterogeneous features of myofibroblastic and smooth muscle differentiation or an undifferentiated phenotype. Hormone receptors were negative in all uterine cases. PDGFRB immunostaining in all cases tested was strong and diffuse, whereas PDGFRA was negative/focal. The most frequent PDGFRB mutations were exon 12 (43%), exon 14 (N666K/S/T) (38%), and exon 18 (D850Y/H/V or insertion/deletion) (19%). The most frequent co-existing genetic alterations (26% to 37%) occurred in CDKN2A/B, TP53, TERT, and MED12. Moreover, PDGFRB-mutant sarcomas had an overall distinct genomic landscape compared with both uterine and soft tissue LMS control groups. These tumors were associated with a highly aggressive clinical course, with frequent distant metastases (81%) and death (76%), regardless of anatomic location, and worse overall survival compared with the 2 LMS control groups. This is the first study documenting recurrent hotspot PDGFRB alterations in high-grade sarcomas, which show a predilection for uterine location and myogenic differentiation that fall short of the diagnostic criteria for LMS. Further studies are needed to investigate the therapeutic potential of kinase inhibitors in this group of tumors. Copyright © 2023 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights reserved. |
| Keywords: | genetics; mutation; pathology; sarcoma; leiomyosarcoma; soft tissue neoplasms; soft tissue tumor; molecular profiling; platelet derived growth factor beta receptor; receptor, platelet-derived growth factor beta; myogenic differentiation; pdgfrb; humans; human; female; pdgfrb protein, human |
| Journal Title: | Modern Pathology |
| Volume: | 36 |
| Issue: | 5 |
| ISSN: | 0893-3952 |
| Publisher: | Nature Research |
| Date Published: | 2023-05-01 |
| Start Page: | 100104 |
| Language: | English |
| DOI: | 10.1016/j.modpat.2023.100104 |
| PUBMED: | 36788091 |
| PROVIDER: | scopus |
| PMCID: | PMC10198815 |
| DOI/URL: | |
| Notes: | Article -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged via PubMed and PDF -- MSK corresponding author is Christina Antonescu -- Export Date: 1 June 2023 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work